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Abstract 
 
Bone metastases frequently occur in the advanced stages of breast cancer. At this stage, 
the disease is deemed incurable. To date, the mechanisms of breast cancer-related 
metastasis to bone are poorly understood. This may be attributed to the lack of appropriate 
animal models to investigate the complex cancer cell-bone interactions. In this study, two 
established tissue-engineered bone constructs (TEBCs) were applied to a breast cancer-
related metastasis model. A cylindrical medical-grade polycaprolactone-tricalcium phosphate 
scaffold produced by fused deposition modelling (scaffold 1) was compared with a tubular 
calcium phosphate-coated polycaprolactone scaffold fabricated by solution electrospinning 
(scaffold 2) for their potential to generate ectopic humanised bone in NOD/SCID mice. While 
the scaffold 1 was found not suitable to generate a sufficient amount of ectopic bone tissue 
due to poor ectopic integration, the scaffold 2 showed excellent integration into the host 
tissue, which did lead to bone formation. To mimic breast cancer cell colonisation to the 
bone, MDA-MB-231, SUM1315 and MDA-MB-231BO breast cancer cells were cultured in 
polyethylene glycol-based hydrogels and implanted adjacent to the TEBCs. Histological 
analysis indicated that the breast cancer cells induced an osteoclastic reaction in the 
TEBCs, demonstrating analogies to breast cancer-related bone metastasis seen in patients. 
 
Keywords: bone tissue engineering, breast cancer, polycaprolactone scaffolds, fused 




Breast cancer is the most common malignancy in women according to the WHO, and over 
half a million women died from this disease in 2011 (DeSantis et al. 2011). Survival rates 
vary from 80% for example in North America, Sweden and Japan to approximately 40-60% 
in middle-income and low-income countries (Coleman M. P. et al. 2008). This wide range 
might be due to inadequate treatment, lack of early detection and poor diagnostic tools, thus 
women are diagnosed with the advanced stage of the disease (Coleman M. P. et al. 2008). 
Despite the availability of well-established treatment modalities, including surgery, chemo-, 
radiation- and anti-hormonal therapy, and therefore high survival rates in high-income 
countries, at least 10-15% of breast cancer patients develop metastases after years of 
disease-free survival (Coleman R. E. and Rubens 1987) (Psaila et al. 2006). Breast cancer-
related metastases mainly affect the skeleton followed by the liver, lung and brain (Coleman 
R. E. and Rubens 1987) (Kozlow and Guise 2005). The skeleton represents the major tissue 
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for breast cancer metastases, about 83% of women with advanced disease suffer from this 
debilitating stage. 
Bone metastases are classified according to their radiographic appearance as osteolytic or 
osteoblastic (Thibaudeau et al. 2014a). Both types of bone lesions are caused by an 
imbalance between bone resorption through activated osteoclasts and new bone formation 
through osteoblasts. Osteolytic lesions show a deficient new bone formation, while 
osteoblastic lesions have a disorganised new bone formation with impaired bone resorption 
(Thibaudeau et al. 2014a). Osteolytic lesions are predominant in breast cancer-related bone 
metastasis (Yu et al. 2012). Symptoms associated with bone metastases are due to 
extensive bone loss and tumour expansion, and include severe bone pain, pathological 
fractures, spinal cord compression and hypercalcaemia (Kozlow and Guise 2005) (Yu et al. 
2012). Current treatment options for bone metastasis are seldom curative and focus on pain 
management (Thibaudeau et al. 2014a). The frequency of pathological fractures can be 
decreased through palliative treatment with anti-resorptive drugs like bisphosphonates and 
the RANKL antibody denosumab (Thibaudeau et al. 2014a). These treatments improve the 
quality of life, but fail to prolong patient survival (Daniele et al. 2011) (Brown et al. 2004). 
The restricted treatment options are due to the fact that underlying mechanisms of breast 
cancer-related bone metastasis are not fully understood which in turn results from the lack of 
appropriate in vitro and in vivo models to study this disease. Current in vivo approaches 
investigate the homing of human breast cancer cells to the murine skeleton in immune-
compromised hosts. These models present two disadvantages. Firstly, injection of cancer 
cells into the murine circulatory system via tail vein or left ventricle bypasses the first steps of 
the metastatic cascade (Kang et al. 2003). Secondly, interspecies phenomena are examined 
as human breast cancer cells interact with the murine bone. Yonou et al. (Yonou et al. 2001) 
were the first to use adult human bone fragments as metastatic target for osteotropic cancer 
cells as opposed to the murine skeleton. However, the route of cancer cell injection 
remained the same (Lau et al. 2013) (Khanna and Hunter 2005). Other models utilised cell 
carrier systems, such as Matrigel or other hydrogels, to induce a human breast tumour at its 
orthotopic site, the murine mammary fat pad, to recapitulate the metastatic cascade but 
failed to generate a bone marrow compartment (Kuperwasser et al. 2005). Since then, only a 
few models used human bone fragments in conjunction with orthotopic breast tumours (Xia 
et al. 2012). However, these models are linked with partial necrosis of the bone fragments 
due to delayed neo-vascularisation, high variability and donor dependency, resulting in poor 
reproducibility (Moreau et al. 2007). A strategy to overcome these complications has been 
the introduction of a bone tissue engineering (TE) approach (Thibaudeau et al. 2014a) 
(Thibaudeau et al. 2014b) (Schuster et al. 2006) (Bersani et al. 2014) (Seib et al. 2015). 
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Scaffolds for the purpose of bone TE need to have a high elastic modulus and an 
interconnected macro-pore structure of 300-500 μm to enhance diffusion rates to and from 
the scaffold centre and to allow the transport of nutrients and by-products (Hutmacher 2000). 
Medical-grade polycaprolactone-tricalcium phosphate (mPCL-TCP) scaffolds produced by 
fused deposition modelling meet the aforementioned requirements (Hutmacher 2000). 
Composite scaffolds represent a combination of bioactive ceramics, such as calcium 
phosphate (CaP), with a polymer, such as mPCL, to combine the favourable mechanical 
properties of the biodegradable polymer with the osteoconductive characteristics of the 
ceramic component (Zhou et al. 2007). Previously, mPCL-TCP scaffolds have been used in 
rat and rabbit skull defect models as well as in a spinal fusion model with promising 
outcomes (Hutmacher and Cool 2007). To further improve the osteoinductivity of these bone 
TE approaches, scaffolds have been used in conjunction with osteogenic progenitor cells 
and growth factors like bone morphogenetic proteins (BMPs) (Arthur et al. 2009) (Biggs et al. 
2009) (Santos et al. 2009). 
This study shows the attempt to translate an orthotopic bone TE approach to an ectopic 
humanised NOD/SCID model. This approach has already been successfully used by our 
group to mimic the invasion of the humanised bone by breast cancer cells upon intra-cardiac 
injection (Thibaudeau et al. 2014a) (Thibaudeau et al. 2014b). Herein, the development of a 
model of direct bone colonisation, by implanting cell-loaded hydrogels adjacent to the tissue-
engineered bone constructs (TEBCs), opposed to the experimental or spontaneous 
metastasis approach, is described. Therefore, two TEBCs with different architectures and 
manufacturing techniques were compared. 
 
2. Materials and Methods 
 
2.1. Isolation of human osteoblasts 
Primary human osteoblasts (hOBs) were isolated from explants obtained from patients 
undergoing knee replacement surgery as approved by the Queensland University of 
Technology and Prince Charles Hospital ethics committees (approval number 0600000232). 
Non-sclerotic, trabecular bone from the tibial plateau was collected, minced, washed and 
transferred into tissue culture flasks containing α-Minimal Essential Medium (α-MEM), 10% 
FBS, penicillin (100 IU/ml) and streptomycin (0.1 mg/ml). 
 
2.2. Cell lines 
MCF10A (non-malignant and non-invasive) and MDA-MB-231 (highly invasive and 
metastatic) cells were purchased from the American Type Culture Collection. SUM1315 cells 
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(invasive) were kindly provided by Prof David Kaplan (Tufts University, US). MDA-MB-
231BO cells (highly invasive) characteristically prone to develop bone metastasis were 
provided by The University of Texas Health Science Center at San Antonio. MCF10A cells 
were cultured in Dulbecco’s Modified Eagle Medium (DMEM)/F-12, EGF (20 ng/ml), insulin 
(0.01 mg/ml) and cholera toxin (100 ng/ml). SUM1315 cells were cultured in DMEM/F-12, 
EGF (10 ng/ml) and insulin (5 μg/ml). MDA-MB-231 and MDA-MB-231-BO cells were 
maintained in DMEM. Each medium contained 10% FBS, penicillin (100 IU/ml) and 
streptomycin (0.1 mg/ml). 
 
2.3. Scaffold fabrication using fused deposition modelling (scaffold 1) 
Composite mPCL-TCP scaffolds were produced by fused deposition modelling (Osteopore 
International, Singapore). Composite scaffold sheets (mPCL:TCP, 80:20) measuring 
100×100×4 mm, with a lay down pattern of 0/60/120º, 100% pore interconnectivity, 380-500 
µm pore size and 70% porosity, were produced as described previously (Zhou et al. 2007). 
Biopsy punches were used to produce cylindrical scaffolds of 4 mm height, with an outer 
diameter of 8 mm and an inner diameter of 4 mm (Fig. 1A-D). Scaffolds were treated with 1 
M NaOH for 6 hrs to hydrolytically cleave mPCL chains and transform ester groups into 
carboxy and hydroxyl groups for increased hydrophilicity. Then, scaffolds were washed with 
PBS and 70% ethanol, followed by evaporation and UV sterilisation for 30 min. Further 
characterisation was performed as reported previously (Reichert et al. 2011). 
 
2.4. Scaffold fabrication using solution electrospinning (scaffold 2) 
Solution electrospun-fabricated mPCL scaffolds were a generous gift from Prof Robert 
Guldberg (George W Woodruff School of Mechanical Engineering, Georgia Institute of 
Technology, US). Characterisation was carried out in the Guldberg group as reported 
previously (Kolambkar et al. 2011). Briefly, to obtain tubular scaffolds, nanometre-sized 
sheets were cut into 13×19 mm rectangular shapes, perforated 1.5 mm apart using a 1 mm 
biopsy punch and wrapped around a steel mandrel to form a tube of 5 mm diameter. 
Overlapping edges were aligned with UV glue (Fig. 1E-F). The fibre diameter was quantified 
using scanning electron microscopy and a custom MATLAB® program. Fibre diameter 
ranged from 51-974 nm, with 82% of the fibres between 50-150 nm. Scaffolds were 300-400 
μm thick, with 80-90% porosity and had a pore size of less than 5 μm (Fig. 1G). Sterilisation 
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2.5. CaP coating of solution electrospun-fabricated scaffolds 
Scaffolds were immersed in 70% ethanol for 30 min under vacuum and treated with 37°C 
pre-warmed 2 M NaOH for 5 min under vacuum, facilitating solution penetration through the 
entire scaffold to enhance the efficacy of alkaline etching. Then, scaffolds were rinsed with 
ddH2O to neutralise the pH. Simulated Body Fluid (SBF-10x) was prepared and filtered (filter 
pore size 0.2 µm) as reported previously (Yang et al. 2008), with pH 6 to increase the 
solution stability and delay CaP precipitation. A 5 min vacuum treatment was performed to 
enable SBF infiltration into the scaffolds, followed by 2.5 hrs SBF incubation at 37°C, with 
SBF changes every 30 min. A 0.5 M NaOH post-treatment for 30 min at 37°C obtained a 
homogenous CaP coating. Then, scaffolds were rinsed with ddH2O, air-dried and placed into 
a desiccator until usage. To evaluate the distribution of the CaP coating, micro-computed 
tomography (μ-CT) analysis, with a 12 μm voxel size, at 45 kV and 177 μA was performed. 
Following parameters were applied: a threshold of 100 Hounsfield Units, a filter width of 0.8 
and filter support of 1.0. Three-dimensional reconstructions were obtained using the 
software package supplied by Scanco Medical AG (Vaquette et al. 2013). 
 
2.6. Cell seeding of scaffolds 
Sterile mPCL-TCP and mPCL-CaP scaffolds were placed into a 24-well plate, and 1.5×105 
hOBs in 50 µl medium were equally distributed onto the scaffolds and incubated at 37ºC/5% 
CO2 to allow cell adhesion. After 2 h, 1 ml of medium was carefully added. Cells were 
cultured in osteogenic medium, containing L-ascorbic acid 2-phosphate (50 μg/ml), β-
glycerophosphate (10 mM) and dexamethasone (0.1 μM) over 4 weeks with medium 
changes twice per week. 
 
2.7. Live/dead assay 
After 4 weeks of 3D culture, a live/dead assay was performed using fluorescein diacetate 
(FDA) and propidium iodide (PI) staining. Samples were rinsed with 37°C pre-warmed 
phenol red-free medium and incubated with FDA (2 µg/ml) and PI (20 µg/ml) staining 
solution prepared in medium at 37ºC/5% CO2 for 15 min. Then, samples were washed in 
PBS, containing CaCl2 (0.901 mM) and MgCl2×6H2O (0.493 mM), and imaged using a Leica 
SP5 laser scanning confocal microscope. 
 
2.8. Assessment of cell morphology 
After 4 weeks of 3D culture, samples were fixed with 4% PFA/PBS for 20 min and 
permeabilised with 0.2% Triton X-100/PBS for 5 min at room temperature. Then, samples 
were washed in PBS and blocked in 2% BSA/PBS for 20 min, followed by incubation with 
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PicoGreen™ (1:1,000) and rhodamine415-conjugated phalloidin (0.3 U/ml) staining solution 
in 2% BSA/PBS for 1 h. DAPI (2.5 µg/ml) staining was used to visualise cell nuclei. Samples 
were washed in PBS to remove any residual staining solution and immersed in PBS and 
imaged using a Leica SP5 laser scanning confocal microscope. 
 
2.9. Implantation of the TEBCs 
Animal experiments were conducted as approved by the Queensland University of 
Technology animal ethics committee (approval number 0900000915). Pre-seeded scaffolds 
were transplanted into the left and right flank by preparing subcutaneous pockets at the 
dorsal site of anaesthetised (25 mg/ml xylazine, 50 mg/ml ketamin, 9-10 µl/g body weight 
i.p.) 7-week old female NOD/SCID mice (ARC, Australia; 3 mice/group). To administer 
rhBMP-7 (10 µg/scaffold; Olympus Biotech, US) and additional hOBs (8×105/scaffold), 110 
μl of fibrin sealant (Tisseel; Baxter, US) was applied to the inner duct of the scaffold 
intraoperatively (Fig. 2). Twelve weeks post-implantation, scaffolds were explanted for 
subsequent analyses. 
 
2.10. Implantation of human non-malignant and malignant breast cell-loaded hydrogels 
Polyethylene glycol (PEG)-based hydrogels were prepared as described previously 
(Loessner et al. 2010) and implanted under general anaesthesia adjacent to the TEBCs. 
Briefly, a 5% PEG-Gln/PEG-MMP-Lys precursor stock solution was diluted to the desired 
PEG concentration in Tris-buffered saline (50 mM, pH 7.6) containing RGD peptide (50 μM) 
and CaCl2 (50 mM). Immediately after adding thrombin-activated factor XIII (10.7 U/ml), the 
breast cancer cell suspension was added (3.5×105 cells/ml). Cell-loaded hydrogel discs were 
formed by sandwiching 25 μl of the reaction mixture between two sterile glass slides, 
separated by 1.5 mm spacers and pre-coated with Sigmacote®, for 30 min at 37ºC/5% CO2 
to allow polymerisation. Then, hydrogels were transferred into 24-well plates and cultured for 
3 days prior to implantation. Additionally, triplicate samples per cell line were cultured for 14 
days to assess cell upon 3D culture. Four weeks post-implantation of cell-loaded hydrogels, 
animals were euthanised, scaffolds retrieved and fixed in 4% PFA for 24 hrs followed by 2% 
PFA for 48 hrs and stored in 70% ethanol for subsequent analysis. Tumour tissues were 
explanted and the tumour dimensions measured with a vernier calliper. 
 
2.11. Micro-CT analysis 
Samples were scanned with a 16 µm voxel size at 55 kV and 145 μA. Following parameters 
were applied: a threshold of 140 Hounsfield Units, a filter width of 1.0 and filter support of 
2.0. X-ray attenuation was correlated to sample density using a standard curve generated by 
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scanning hydroxyapatite phantoms with known mineral density. Three-dimensional 
reconstructions were obtained using the software package supplied by Scanco Medical AG 




Samples were treated with 10% EDTA for at least 10 days to assure sufficient decalcification 
prior to paraffin embedding and serial sectioning (5 µm) using standard procedures. 
Samples were stained with Mayer’s haematoxylin and eosin (H&E), human-specific 
antibodies (Table 1) and visualised using a Zeiss Axio Imager A.1 with an AxioCam MRc 
Rev 3 digital camera. 
 
2.13. Tartrate resistant acid phosphatase (TRAP) staining and quantification of osteoclast 
numbers 
To detect osteoclasts, TRAP staining was performed as described previously (Thibaudeau et 
al. 2014b). Briefly, deparaffinised sections were treated with 0.2 M acetate buffer (0.2 M 
sodium acetate, 50 mM L(+) tartaric acid in ddH2O, pH 5.0) for 20 min at room temperature. 
Then, samples were incubated with naphtol AS-MX phosphate (0.5 mg/ml) and fast red TR 
salt (1.1 mg/ml) in 0.2 M acetate buffer for up to 4 hrs at 37ºC until osteoclasts appeared 
bright red. Samples were counterstained with Mayer’s haematoxylin and visualised using a 
Zeiss Axio Imager A.1 with an AxioCam MRc Rev 3 digital camera. The number of 
osteoclasts was determined using the ImageJ software (NIH). For each group, 16 images 
representing the total area of new bone formation, taken at two different depths of the 
scaffold, were analysed. The number of osteoclasts was counted and normalised to the 
length of the respective bone line. 
 
2.14. Statistical analysis 
Datasets were tested for normality using SPSS software (IBM). Normally distributed data 
were then tested for statistical differences using a Student t-test or one-way ANOVA. P<0.05 
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3. Results 
 
3.1. Similar morphology and viability of hOBs grown on different scaffolds 
 
Morphology and viability of hOBs was assessed after 4 weeks of 3D culture on both mPCL-
TCP and mPCL-CaP scaffolds by bright-field (Suppl.Fig. 1A, D) and confocal microscopy 
(Suppl.Fig. 1B-C, E-F), revealing an elongated and spindle-shaped morphology of hOBs 
forming a dense, interconnected 3D network around the pores of both constructs. Cell 
viability was greater than 90% (Suppl.Fig. 1C, F). 
 
3.2. Tubular mPCL-CaP scaffolds showed a superior incorporation into murine soft tissues 
 
After 4 weeks of in vitro culture and osteogenic induction, hOB-seeded constructs were 
implanted into the flanks of female NOD/SCID mice. No adverse reaction was observed 
post-implantation of scaffolds, and scaffolds were well-tolerated over the duration of the 
experiments. Twelve weeks post-implantation, scaffolds were explanted. The delicate skin of 
NOD/SCID mice was not strong enough to aid the integration of the mPCL-TCP scaffold 
(scaffold 1; Suppl.Fig. 2A-D) in comparison to the mPCL-CaP scaffold (scaffold 2; Suppl.Fig. 
2F) into the murine soft tissues due to its mechanical properties. Both TEBCs were well-
vascularised at the time of explantation (Suppl.Fig. 2E, F). Micro-CT analysis showed that 
the mineralised tissue was distributed equally throughout both scaffolds and that the mPCL-
TCP scaffold had a higher amount of mineralised tissue close to the muscle, but less 
mineralised tissue close to the skin (Fig. 3A, E). H&E staining revealed new bone (NB) 
formation and connective tissue (CT) in both scaffolds (Fig. 3B-C, F-G). TRAP staining 
indicated the presence of osteoclasts actively degrading the bone-like matrix in both 
scaffolds, with the mPCL-CaP scaffold group showing a higher amount of TRAP-positive 
cells (Fig. 3D, H). Although both scaffolds had equal osteoinductive properties, the mPCL-
CaP scaffold (scaffold 2) was used for all subsequent experiments due to its better 
integrative and bone resorption features. 
 
3.3. Distincitve cell morphologies of non-malignant and breast cancer cells grown within 
hydrogels 
 
To assess the morphological differences of the all cell lines tested upon 3D cultures, cells 
were grown for 14 days within PEG-based hydrogels. Each cell line showed a distinct 
morphology within the hydrogels as visualised by immunofluorescent staining and confocal 
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laser scanning microscopy. Non-malignant MCF10A cells formed regular-shaped spheroids 
and a cell layer on top of the hydrogel (Suppl.Fig. 3A). SUM1315 cells formed only a few 
multicellular spheroids and remained mainly as single cells (Suppl.Fig. 3B). No spheroid 
formation was observed for the MDA-MB-231 cells which were evenly distributed as single 
cells throughout the hydrogel (Suppl.Fig. 3C). In contrast, MDA-MB-231BO cells formed 
grape-like loose cell clusters of difference sizes upon 3D culture (Suppl.Fig. 3D). 
 
3.4. Implantation of invasive breast cancer cells using a hydrogel carrier system led to 
tumour growth in vivo 
 
Cell-loaded hydrogels were implanted into the flanks of female NOD/SCID mice in a second 
surgical procedure after 8 weeks post-implantation of the pre-seeded mPCL-CaP scaffolds 
(Suppl.Fig. 3E-F). Scaffolds and the cell-loaded hydrogels were fully integrated into the 
murine soft tissue and were well-vascularised (Suppl.Fig. 3G-H). Initial tumour growth was 
observed 2 weeks post-implantation of MDA-MB-231 and MDA-MB-231BO cells reaching a 
terminal volume of 1 cm3 after 4 weeks. No tumour growth was seen for SUM1315 cells after 
4 weeks post-implantation which might be due to their slow growth rate (Kuperwasser et al. 
2005). As expected, non-malignant MCF10A did not form tumours. The human origin of the 
osteoblasts and other human cellular and matrix components, present in the mPCL-CaP 
scaffold (Fig. 4A), was demonstrated by immunohistochemical staining with human-specific 
antibodies directed against nuclear mitotic apparatus protein (hs-NuMA; Fig. 4B-C), 
osteocalcin (hs-OC; Fig. 4D), collagen type-I (hs-Col-I; Fig. 4E) and von Willebrand Factor 
(hs-vWF; Fig. 4E). 
 
3.5. Development of the organ bone and enhanced osteoclastic activity upon presence of 
highly metastatic breast cancer cells 
 
To explore the crosstalk between breast tumours and the TEBCs, μ-CT and histological 
analyses were performed 12 weeks post-implantation of the hOB-seeded mPCL-CaP 
scaffolds and 4 weeks post-implantation of cell-loaded hydrogels. Micro-CT analysis 
revealed a high ratio of mineralised tissue (average 21 ± 4%) in all groups (Fig. 5A, E, I, M). 
The BV/TV ratio did not significantly change in any of the malignant cell groups (SUM1315: 
0.022 ± 0.013; MDA-MB-231: 0.092 ± 0.041; MDA-MB-231BO: 0.040 ± 0.005) compared to 
the non-malignant control group (MCF10A: 0.034 ± 0.017; Fig.6A), thus indicating no major 
changes in the cancer cell-induced osteolysis. There was a significantly lower BC/TV in the 
SUM1315 tumour group compared to the MDA-MB-231BO tumour group (P<0.05). Calcified 
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areas were also detected in the MDA-MB-231 (Fig. 5I) and MDA-MB-231BO (Fig. 5M) 
tumours. H&E staining revealed residual PCL in all groups and indicated different tissue 
types, including new bone (NB), bone marrow (BM), fibrous connective tissue (CT) and 
tumour tissue (T), with clear blood vessel formation (Fig. 5B-C, F-G, J-K, N-O). New bone 
formation was detected in the scaffold area and in the hollow parts of the scaffold, where 
hOBs in addition to rhBMP-7 had been administered. TRAP staining (Fig. 5D, H, L, P; Fig. 
3H) indicated a significant increased number of TRAP-positive cells for SUM1315 (0.52 ± 
0.11 mm-1), MDA-MB-231 (0.53 ± 0.08 mm-1) and MDA-MB-231-BO (0.41 ± 0.02 mm-1) 
tumours and the scaffold only (0.26 ± 0.01 mm-1) at the bone interface compared to the non-
malignant MCF10A cells (0.03 ± 0.02 mm-1; P<0.05; Fig. 6B). The number of TRAP-positive 
cells and the BV/TV ratio were the highest in the MDA-MB-231 tumour group. MDA-MB-231-
BO cells formed significantly bigger tumours (272.3 ± 53.8 mm3; P<0.05) compared to 
SUM1315 cells (37.75 ± 16.0 mm3), while MDA-MB-231 cells had medium-sized tumours 




The development of breast cancer-related bone metastases is a highly dynamic and 
complex process, which can be mimicked in an in vivo disease model consisting of the two 
main components – a humanised breast tumour and a humanised organ bone. To achieve 
sufficient bone formation through TE strategies, the first-generation FDA-approved mPCL 
scaffold was combined with bone marrow-derived stromal cells that had to be immobilised 
onto the scaffold using fibrin sealant because of its poor protein and cell adhesive properties. 
To circumvent this approach, a second-generation composite scaffold made from mPCL and 
TCP was established by fused deposition modelling (Zhou et al. 2007). The advantages of 
composite scaffolds are their improved biomechanical and degradation properties, increased 
strength via the ceramic phase, toughness and plasticity via the polymer phase (Hutmacher 
and Cool 2007). These improvements have resulted in advanced cell seeding, adhesion, 
control and/or incorporation of biological factors like BMPs (Rai et al. 2005). In this study, a 
high seeding efficiency 8 hrs after administration of hOBs onto the mPCL-TCP scaffold was 
achieved (data not shown). 
Porcine bone marrow-derived stromal cells in conjunction with mPCL-TCP scaffolds were 
used in a subcutaneous rat model, showing sufficient bone formation (Zhou et al. 2007). 
Bone regenerative applications using mPCL-TCP scaffolds, which was loaded with collagen-
type I and rhBMP-2, demonstrated a full closure of a critical-sized rat calvarial defect 15 
weeks post-implantation (Sawyer et al. 2009). Neither short-term nor long-term foreign body 
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reactions were detectable underscoring the high immunocompatibility of mPCL (Sawyer et 
al. 2009). In this study, osteogenic progenitor cells and rhBMP-7 were used to further 
increase the osteoinductivity and biological activity of the mPCL-TCP scaffolds, but with 
mixed results (scaffold 1). The major differences between this study and the aforementioned 
studies were the subcutaneous localisation of the scaffold and the cell type used. Our group 
has already shown that ovine osteoblasts grown on mPCL-TCP scaffolds and addition of 
rhBMP-7 resulted in a sufficient amount of bone (Reichert et al. 2011), but yet was not able 
to achieve similar results in the present study using human osteogenic progenitor cells. One 
reason might be the mechanical properties of the scaffold as they are favourable for bone 
TE in orthotopic defect models but can present pitfalls in humanised subcutaneous 
NOD/SCID mice models. 
 
Hence, it was sought to find a suitable scaffold to engineer a humanised bone 
microenvironment and upon this to develop an in vivo disease model to investigate cancer-
related metastasis to this human bone equivalent. Therefore, a bone TE approach for the in 
vitro culture of hOBs was combined with the in vitro 3D culture of non-malignant and 
malignant breast cells within PEG-based hydrogels. Upon implantation of the TEBCs 
(scaffold 2), a complex organ bone composed of human and murine elements was formed. 
In addition, the implantation of cell-loaded hydrogels acted as delivery system of human non-
malignant and malignant breast cells in NOD/SCID mice. 
The mechanical properties are critical for the treatment of bone defects, where an intrinsic 
stability of the scaffold is desired, but were causing complication in the ectopic side in the 
NOD/SCID model. The delicate skin of NOD/SCID mice was not strong enough to aid the 
integration of the scaffold into the soft tissue of the murine flanks to the same extent as 
reported for the ectopic bone formation in a rat model (Zhou et al. 2007). This incomplete 
integration might be responsible for the apparent gradient in bone formation from the skin 
towards the muscle. Thus, a mPCL-CaP scaffold (scaffold 2) was chosen for the breast 
cancer-related metastasis experiments (Kolambkar et al. 2010) (Kolambkar et al. 2011). The 
major differences between both scaffolds are the fabrication technique, fused deposition 
modelling versus solution electrospinning, and the scaffold design, cylindrical versus tubular. 
In line with a previous study (Kolambkar et al. 2010), hOBs formed a dense cell sheet when 
grown on the perforated mPCL-CaP scaffold and remained viable over 4 weeks in vitro. 
Bone TE properties of these scaffolds were successfully established in a rat femoral defect 
model, in which scaffolds were combined with rhBMP-2 via an alginate hydrogel, leading to 
new bone formation and bridging the defect within 12 weeks post-implantation (Kolambkar et 
al. 2011). In the presented study, the orthotopic approach (Kolambkar et al. 2011) was 
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translated to an ectopic setting by improving its bioactivity. The addition of CaP coating, 
hOBs, which have been osteogenically stimulated pre-implantation, and rhBMP-7 resulted in 
a humanised organ bone at an ectopic site in NOD/SCID mice, allowing the study of cancer-
related bone metastasis. 
Only few groups use a bone TE approach to study the mechanisms of bone metastasis in 
ectopic NOD/SCID models. Moreau et al. (Moreau et al. 2007) utilised a biodegradable silk 
scaffold together with human mesenchymal stem cells (hMSCs) and rhBMP-2. Development 
of matured bone occurred 7 weeks after in vitro culture under osteogenic conditions, but did 
not mediate breast cancer cell colonisation (Moreau et al. 2007). Instead, the more primitive 
bone microenvironment resulted in a higher amount of breast cancer cell colonisation 3 
months post-implantation at its orthotopic site, the mammary fat pad. The application of this 
silk scaffold combined with either hMSC or rhBMP-2 had the highest effect on metastatic 
spread compared to their combination (Moreau et al. 2007). This suggests breast cancer 
cells homed towards hMSCs grown on the silk scaffold rather than towards the tissue-
engineered bone construct (Moreau et al. 2007). The presented TE approach herein utilised 
hOBs in addition to rhBMP-7 in fibrin sealant and aimed for the generation of mature human 
bone as target tissue for breast cancer cell colonisation. Thus, it is of utmost importance to 
represent all elements of the organ bone in an ectopic bone assay that includes mineralised 
tissue, osteoblasts, osteocytes, osteoclasts and bone marrow. Several other studies have 
shown that TE approaches lead to mineralised tissue formation in ectopic bone models, but 
without the development of bone marrow (Kuperwasser et al. 2005) (Moreau et al. 2007) 
(Roldan et al. 2010). 
Our bone TE approach indicated that the newly formed bone is of human origin. 
Immunohistochemical analysis indicated the presence of matrix-embedded osteocytes of 
human origin as well as human-derived osteocalcin and collagen type-I in the TEBCs. The 
appearance of human spindle-shaped cells in the connective and cartilaginous tissues 
suggests that the implanted hOBs and not the murine cells mainly participated in the 
endochondral bone formation. The human-derived bone-specific matrix proteins osteocalcin 
and collagen type-I were mostly located in the center of the organ bone, demonstrating that 
the outer cortical-like shell surrounding the scaffold is a chimera of both human and murine 
extracellular matrix. This finding is consistent with our previous approach (Thibaudeau et al. 
2014a) (Thibaudeau et al. 2014b). To date, several groups ulilised approaches, such as 
Matrigel or fibrin gels, other than tissue-engineered bone constructs to humanise the bone 
marrow microenvironment to study for example normal and malignant hematopoiesis 
(Sacchetti et al. 2007) (Chen et al. 2012) (Reinisch et al. 2016). 3D bioprinting can be used 
to generate a biomimetic bone matrix that consists of gelatine-based hydrogels loaded with 
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human osteoblasts or human bone marrow-derived MSCs to study their functional 
interaction with breast cancer cells (Zhou et al. 2016). 
 
A well-established hydrogel model was used to deliver human breast cancer cells. Evidently, 
3D cell culture platforms mimic physiological cellular microenvironment, mimicking the 
natural cellular behaviour compared to 2D cultures on tissue culture plastic. Our group 
established PEG-based hydrogels as 3D platform for human ovarian cancer cells (Loessner 
et al. 2010). These synthetically-derived biomaterials are well-defined opposed to other 
commonly-used biomaterials in the cancer research, like Matrigel, which harbour high batch-
to-batch variations that complicate data analysis (Loessner et al. 2010). To examine the 
integral step of the metastatic cascade, the bone colonisation by breast cancer cells, PEG-
based hydrogels were used to implant breast cancer cells adjacent to the TEBCs. Tumour 
formation was observed within 4 weeks post-implantation. Macroscopic analysis upon 
explantation showed sufficient vascularisation of the tumours and the TEBCs as well as 
blood vessels shared by both. A significantly higher number of osteoclasts were found in the 
TEBCs in conjunction with the invasive breast cancer cells compared to the control. These 
findings indicate reciprocal interactions between the tumour and TEBCs. However, future 
experiments need to be performed to further confirm these interactions. 
 
The majority of ectopic bone models utilise human bone chips (Kuperwasser et al. 2005) or 
silk scaffolds seeded with hMSCs (Moreau et al. 2007) that are implanted into immune-
suppressed animals. While the implanted human bone chips are often poorly vascularised 
and have a high dehiscence rate, in turn, previous bone TE approaches often failed to 
produce sufficient bone volume to allow the analysis of reciprocal interactions with breast 
cancer cells. In this study, a notably large bone volume in NOD/SCID mice was engineered. 
Strikingly, this bone comprises hallmarks of the organ bone, such as bone marrow, reticular 
and adipocytic stroma, hematopoietic cells, bone-lining osteoblasts and osteoclasts. This in 
vivo disease model significantly increased osteoclast recruitment, thus recapitulating 
clinically relevant osteolytic lesions. It should be noted that this humanised model using a 
subcutaneous approach in NOD/SCID mice still harbours features of both species, human 
and murine. As NOD/SCID mice are hosting the human TEBCs, it is assumed that the 
vascularisation, osteoclasts and the bone marrow are provided by the murine host. Our 
group has shown that osteoblasts remained at the implantations site within the mineralized 
matrix when using ovine osteoblasts instead of hOBs in conjunction with rhBMP-7 and the 
identical mPCL-TCP scaffold (Reichert et al. 2011). Hence, it is assumed that hOBs also 
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remain within their bone-like matrix deposited onto the scaffold, thus providing a humanised 
organ bone within the murine host. 
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Figure 1. A. Cylindrical mPCL-TCP scaffold produced by fused deposition modelling 
(scaffold 1). B-D. Scanning electron micrographs of mPCL-TCP scaffold. E-F. Tubular 
mPCL-CaP scaffold produced by solution electrospinning (scaffold 2); image reproduced 
from (Kolambkar et al. 2011). G. Scanning electron micrograph of mPCL-CaP scaffold 
sheets prior to tubular shaping, with random non-woven fibres and a broad range fibre 
diameter (51-974 nm); image reproduced from (Kolambkar et al. 2011). 
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Figure 2. Primary human osteoblasts (hOBs) were seeded onto mPCL-TCP and mPCL-CaP 
scaffolds in osteogenic culture conditions. After 4 weeks, hOB-seeded scaffolds were 
combined with rhBMP-7-containing fibrin sealant and implanted into the flanks of NOD/SCID 
mice subcunateously. After 12 weeks, scaffolds were explanted for subsequent analyses. 
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Figure 3. A, E. Micro-CT images showing scattered mineralised tissue in the mPCL-TCP 
scaffold and equally distributed mineralised tissue in the mPCL-CaP scaffold. B-C, F-G. H&E 
staining demonstrate new bone formation in both scaffolds (squared boxes represent areas 
if higher magnification shown in C, G; NB, new bone; CT, connective tissue; PCL, 
polycaprolactone); images shown in A-D reproduced from (Quent et al. 2016). D, H. TRAP 
staining reveals osteoclastic activity in both scaffolds, with more TRAP-positive cells in the 
mPCL-CaP scaffold (black arrows; NB, new bone; PCL, polycaprolactone). 
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Figure 4. A. H&E staining of the mPCL-CaP scaffold confirmed new bone and bone marrow 
formation. B-C. Human-derived osteoblasts are indicated by positive staining for nuclear 
mitotic apparatus protein (hs-NuMA; squared box represents area if higher magnification 
shown in C). D-E. The presence of bone-specific matrix proteins is detected by human-
specific antibodies against osteocalcin (hs-OC) and collagen type-I (hs-Col-I). F. Other 
human-derived factors within the bone and bone marrow compartment are indicated by 
positive staining for human-specific von Willebrand Factor (hs-vWF; NB, new bone; BM, 
bone marrow; CT, connective tissue; CART, cartilage). 
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Figure 5. A, E, I, M. Micro-CT analysis shows large amounts of mineralised tissues in all 
experimental groups (inserts represent cross-sections). B-C, F-G, J-K, N-O. H&E staining 
correlates with the mineralised tissue detected by μ-CT and indicates new bone formation, 
tumour and connective tissues and the presence of bone marrow (squared boxes represent 
areas if higher magnification shown in C, G, K, O; NB, new bone; CT, connective tissue; 
PCL, polycaprolactone; BM, bone marrow; M, murine muscle; T, tumor tissue). D, H, L, P. 
TRAP staining is apparent in SUM1315, MDA-MB-231 and MDA-MB-231BO groups (black 
arrows; squared box represent area if higher magnification shown in the insert), while no 
TRAP-positive cells are present in the non-malignant MCF10A group (NB, new bone; CT, 
connective tissue; PCL, polycaprolactone; T, tumor tissue). 
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Figure 6. A. BV/TV did not significantly change in any of the tumour groups compared to the 
non-malignant control. BC/TV was significantly decreased in the SUM1315 tumour group 
compared to the MDA-MB-231BO tumour group (n=3, mean ± SEM, * P<0.05). B. Number 
of osteoclasts found on the bone interface was significantly increased in the scaffold only 
group and in the presence of SUM1315, MDA-MB-231 and MDA-MB-231BO cells compared 
to the non-malignant MCF-10 cells (n=3, mean ± SEM, * P<0.05). C. Tumour volume was 
calculated using the tumour dimensions measured with a vernier calliper; non-malignant 
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Table 1. List of antibodies used for immunohistochemistry. 
Antibody Name Company Cat.No. Host species Dilution 
NuMA Nuclear mitotic apparatus 
protein 
Epitomics S2825 rabbit, 
polyclonal 
1:100 










vWF von Willebrand Factor Merck Millipore ab7356 rabbit, 
polyclonal 
1:300 
 
 
 
